
Our model for value creation
Our model for value creation
Financial resources
Intellectual capital
(1) The Patent Cooperation Treaty (PCT) facilitates the procedure to obtain patent protection internationally.
(2) “Patents and innovation against cancer. Evidence from patent and company data”, European Patent Office, February 2024, epo.org.
R&D resources
Industrial resources
Human resources
Environmental capital
Environmental capital
Over 60 active scientific partnerships and collaborations
Number of projects ongoing with patient organizations: 250 (September 2024)
Financial
2023-2024 Group revenue: €5.9 bn
Scientific and therapeutic
29 brand-name medicines
(3) 2023 Ranking of pharmaceutical companies by reputation following the PatientView survey of patient organizations throughout the world.
Social
Servier was ranked 2nd in the Happy Trainees World ranking for the third consecutive year, also ranked 1st in France
(4) Annual engagement survey conducted with the independent Gallup Institute – 2023 results
Environnemental
5% reduction in greenhouse gas emissions (across scopes 1 and 2) compared with 2022-2023
Sponsorship and solidarity
22 non-profit organizations received financial donations through the Mécénat Servier Charity Fund in 2023-2024
Innovate
An independent Group with a long-term vision enabled by its governance model led by a non-profit foundation, the Fondation Internationale de Recherche Servier.
Vocation
Committed to therapeutic progress to serve patient needs
Our vision
Founded to serve health, our Group aspires to make a meaningful social impact for patients and for a sustainable world